Acquired Company

Novo Nordisk completed its acquisition of Akero Therapeutics for $54 per share in cash plus a $6 per share contingent value right, with Akero becoming a wholly owned subsidiary of Novo Nordisk on December 9, 2025.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California. Show more

601 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA

https://akerotx.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

4.499B

52 Wk Range

$31.80 - $57.35

Previous Close

$54.65

Open

$54.65

Volume

N/A

Day Range

$54.65 - $54.65

Enterprise Value

3.762B

Cash

176M

Avg Qtr Burn

-67.17M

Insider Ownership

1.46%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Efruxifermin (FGF-21 mimetic) Details Compensated cirrhosis (F4) due to MASH	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3, Non-invasively diagnosed MASLD (F1–F4 fibrosis)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin Details Compensated cirrhosis (F4, Child-Pugh A) due to MASH	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.